{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:22:52Z","timestamp":1791645772104,"version":"4.3.4"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"36","license":[{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81930107"],"award-info":[{"award-number":["81930107"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81825023"],"award-info":[{"award-number":["81825023"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81803764"],"award-info":[{"award-number":["81803764"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims\u2003<\/jats:title>\n                  <jats:p>Despite considerable therapeutic advances, there is still a dearth of evidence on the molecular determinants of cardiac hypertrophy that culminate in heart failure. Neuraminidases are a family of enzymes that catalyze the cleavage of terminal sialic acids from glycoproteins or glycolipids. This study sought to characterize the role of neuraminidases in pathological cardiac hypertrophy and identify pharmacological inhibitors targeting mammalian neuraminidases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results\u2003<\/jats:title>\n                  <jats:p>Neuraminidase 1 (NEU1) was highly expressed in hypertrophic hearts of mice and rats, and this elevation was confirmed in patients with hypertrophic cardiomyopathy (n\u2009=\u20097) compared with healthy controls (n\u2009=\u20097). The increased NEU1 was mainly localized in cardiomyocytes by co-localization with cardiac troponin T. Cardiomyocyte-specific NEU1 deficiency alleviated hypertrophic phenotypes in response to transverse aortic constriction or isoproterenol hydrochloride infusion, while NEU1 overexpression exacerbated the development of cardiac hypertrophy. Mechanistically, co-immunoprecipitation coupled with mass spectrometry, chromatin immunoprecipitation, and luciferase assays demonstrated that NEU1 translocated into the nucleus and interacted with GATA4, leading to Foetal gene (Nppa and Nppb) expression. Virtual screening and experimental validation identified a novel compound C-09 from millions of compounds that showed favourable binding affinity to human NEU1 (KD = 0.38\u2009\u03bcM) and effectively prevented the development of cardiac remodelling in cellular and animal models. Interestingly, anti-influenza drugs zanamivir and oseltamivir effectively inhibited mammalian NEU1 and showed new indications of cardio-protection.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions\u2003<\/jats:title>\n                  <jats:p>This work identifies NEU1 as a critical driver of cardiac hypertrophy and inhibition of NEU1 opens up an entirely new field of treatment for cardiovascular diseases.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehab347","type":"journal-article","created":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T11:10:36Z","timestamp":1621595436000},"page":"3770-3782","source":"Crossref","is-referenced-by-count":63,"title":["Neuraminidase 1 is a driver of experimental cardiac hypertrophy"],"prefix":"10.1093","volume":"42","author":[{"given":"Qian-Qian","family":"Chen","sequence":"first","affiliation":[{"name":"State Key Laboratory of Natural Medicines, China Pharmaceutical University , No. 24 Tongjia Lane, Nanjing 210009, China"},{"name":"School of Traditional Chinese Pharmacy, China Pharmaceutical University , No. 639 Longmian Road, Nanjing 211198, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaoxiang","family":"Ma","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Pharmacy, China Pharmaceutical University , No. 639 Longmian Road, Nanjing 211198, China"},{"name":"Clinical Metabolomics Center, China Pharmaceutical University , No. 639 Longmian Road, Nanjing 211198, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Feng","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural Medicines, China Pharmaceutical University , No. 24 Tongjia Lane, Nanjing 210009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3103-0873","authenticated-orcid":false,"given":"Yuan-Yuan","family":"Cai","sequence":"additional","affiliation":[{"name":"Clinical Metabolomics Center, China Pharmaceutical University , No. 639 Longmian Road, Nanjing 211198, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Yuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural Medicines, China Pharmaceutical University , No. 24 Tongjia Lane, Nanjing 210009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Ting","family":"Wei","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural Medicines, China Pharmaceutical University , No. 24 Tongjia Lane, Nanjing 210009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Pan","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural Medicines, China Pharmaceutical University , No. 24 Tongjia Lane, Nanjing 210009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujun","family":"Jiang","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Pharmacy, China Pharmaceutical University , No. 639 Longmian Road, Nanjing 211198, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibei","family":"Xiao","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural Medicines, China Pharmaceutical University , No. 24 Tongjia Lane, Nanjing 210009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingxi","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Sir Run Run Hospital, Nanjing Medical University , No. 109 Longmian Road, Nanjing 211166, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangping","family":"Song","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College , No. 167 Beilishi Road, Beijing 100037, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural Medicines, China Pharmaceutical University , No. 24 Tongjia Lane, Nanjing 210009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural Medicines, China Pharmaceutical University , No. 24 Tongjia Lane, Nanjing 210009, China"},{"name":"School of Traditional Chinese Pharmacy, China Pharmaceutical University , No. 639 Longmian Road, Nanjing 211198, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0728-4475","authenticated-orcid":false,"given":"Lian-Wen","family":"Qi","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural Medicines, China Pharmaceutical University , No. 24 Tongjia Lane, Nanjing 210009, China"},{"name":"Clinical Metabolomics Center, China Pharmaceutical University , No. 639 Longmian Road, Nanjing 211198, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,6,28]]},"reference":[{"key":"2022102612014274600_ehab347-B1","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIRCULATIONAHA.115.013894","article-title":"Inhibition of hypertrophy is a good therapeutic strategy in ventricular pressure overload","volume":"131","author":"Schiattarella","year":"2015","journal-title":"Circulation"},{"key":"2022102612014274600_ehab347-B2","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0140-6736(12)60397-3","article-title":"Hypertrophic cardiomyopathy","volume":"381","author":"Maron","year":"2013","journal-title":"Lancet"},{"key":"2022102612014274600_ehab347-B3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41569-018-0007-y","article-title":"Mechanisms of physiological and pathological cardiac hypertrophy","volume":"15","author":"Nakamura","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"2022102612014274600_ehab347-B4","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0735-1097(99)00630-0","article-title":"Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling","volume":"35","author":"Cohn","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2022102612014274600_ehab347-B5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.stem.2012.10.010","article-title":"Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells","volume":"12","author":"Lan","year":"2013","journal-title":"Cell Stem Cell"},{"key":"2022102612014274600_ehab347-B6","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nature14332","article-title":"Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease","volume":"519","author":"Lee","year":"2015","journal-title":"Nature"},{"key":"2022102612014274600_ehab347-B7","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature13596","article-title":"A long noncoding RNA protects the heart from pathological hypertrophy","volume":"514","author":"Han","year":"2014","journal-title":"Nature"},{"key":"2022102612014274600_ehab347-B8","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.jacc.2017.07.789","article-title":"Bone marrow-derived tenascin-c attenuates cardiac hypertrophy by controlling inflammation","volume":"70","author":"Song","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2022102612014274600_ehab347-B9","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/s41586-019-0895-y","article-title":"PKG1-modified TSC2 regulates mTORC1 activity to counter adverse cardiac stress","volume":"566","author":"Ranek","year":"2019","journal-title":"Nature"},{"key":"2022102612014274600_ehab347-B10","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"2022102612014274600_ehab347-B11","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"key":"2022102612014274600_ehab347-B12","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1093\/glycob\/cws057","article-title":"Mammalian sialidases: physiological and pathological roles in cellular functions","volume":"22","author":"Miyagi","year":"2012","journal-title":"Glycobiology"},{"key":"2022102612014274600_ehab347-B13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3389\/fmicb.2019.00039","article-title":"Influenza virus neuraminidase structure and functions","volume":"10","author":"McAuley","year":"2019","journal-title":"Front Microbiol"},{"key":"2022102612014274600_ehab347-B14","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.cellsig.2009.09.038","article-title":"Neu1 desialylation of sialyl alpha-2,3-linked beta-galactosyl residues of TOLL-like receptor 4 is essential for receptor activation and cellular signaling","volume":"22","author":"Amith","year":"2010","journal-title":"Cell Signal"},{"key":"2022102612014274600_ehab347-B15","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.2337\/db12-1825","article-title":"Positive regulation of insulin signaling by neuraminidase 1","volume":"62","author":"Dridi","year":"2013","journal-title":"Diabetes"},{"key":"2022102612014274600_ehab347-B16","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1074\/jbc.M109.055475","article-title":"Regulation of phagocytosis in macrophages by neuraminidase 1","volume":"285","author":"Seyrantepe","year":"2010","journal-title":"J Biol Chem"},{"key":"2022102612014274600_ehab347-B17","doi-asserted-by":"crossref","first-page":"8214","DOI":"10.1074\/jbc.M111.292888","article-title":"NEU1 sialidase expressed in human airway epithelia regulates epidermal growth factor receptor (EGFR) and MUC1 protein signaling","volume":"287","author":"Lillehoj","year":"2012","journal-title":"J Biol Chem"},{"key":"2022102612014274600_ehab347-B18","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.2353\/ajpath.2008.071081","article-title":"Neuraminidase-1, a subunit of the cell surface elastin receptor, desialylates and functionally inactivates adjacent receptors interacting with the mitogenic growth factors PDGF-BB and IGF-2","volume":"173","author":"Hinek","year":"2008","journal-title":"Am J Pathol"},{"key":"2022102612014274600_ehab347-B19","doi-asserted-by":"crossref","first-page":"14689","DOI":"10.1074\/jbc.RA118.004589","article-title":"Sialidase down-regulation reduces non-HDL cholesterol, inhibits leukocyte transmigration, and attenuates atherosclerosis in ApoE knockout mice","volume":"293","author":"White","year":"2018","journal-title":"J Biol Chem"},{"key":"2022102612014274600_ehab347-B20","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.vph.2018.01.005","article-title":"A positive feedback loop between IL-1\u03b2, LPS and NEU1 may promote atherosclerosis by enhancing a pro-inflammatory state in monocytes and macrophages","volume":"103\u2013105","author":"Sieve","year":"2018","journal-title":"Vascul Pharmacol"},{"key":"2022102612014274600_ehab347-B21","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1194\/jlr.M027300","article-title":"Hypomorphic sialidase expression decreases serum cholesterol by downregulation of VLDL production in mice","volume":"53","author":"Yang","year":"2012","journal-title":"J Lipid Res"},{"key":"2022102612014274600_ehab347-B22","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s00395-020-00821-z","article-title":"Neuraminidase-1 promotes heart failure after ischemia\/reperfusion injury by affecting cardiomyocytes and invading monocytes\/macrophages","volume":"115","author":"Heimerl","year":"2020","journal-title":"Basic Res Cardiol"},{"key":"2022102612014274600_ehab347-B23","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41586-020-2797-4","article-title":"Cells of the adult human heart","volume":"588","author":"Litvi\u0148ukov\u00e1","year":"2020","journal-title":"Nature"},{"key":"2022102612014274600_ehab347-B24","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41569-019-0315-x","article-title":"Reappraising the role of inflammation in heart failure","volume":"17","author":"Adamo","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"2022102612014274600_ehab347-B25","doi-asserted-by":"crossref","first-page":"e0170781","DOI":"10.1371\/journal.pone.0170781","article-title":"Mononuclear phagocytes are dispensable for cardiac remodeling in established pressure-overload heart failure","volume":"12","author":"Patel","year":"2017","journal-title":"PLoS One"},{"key":"2022102612014274600_ehab347-B26","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nrm1983","article-title":"Regulation of cardiac hypertrophy by intracellular signalling pathways","volume":"7","author":"Heineke","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2022102612014274600_ehab347-B27","doi-asserted-by":"crossref","first-page":"7543","DOI":"10.1073\/pnas.94.14.7543","article-title":"Angiotensin II type1a receptor gene expression in the heart: AP-1 and GATA-4 participate in the response to pressure overload","volume":"94","author":"Herzig","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022102612014274600_ehab347-B28","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1152\/ajpcell.00173.2007","article-title":"Serum response factor neutralizes Pur alpha- and Pur beta-mediated repression of the fetal vascular smooth muscle alpha-actin gene in stressed adult cardiomyocytes","volume":"294","author":"Zhang","year":"2008","journal-title":"Am J Physiol Cell Physiol"},{"key":"2022102612014274600_ehab347-B29","doi-asserted-by":"crossref","first-page":"30245","DOI":"10.1074\/jbc.M102174200","article-title":"The transcription factors GATA4 and GATA6 regulate cardiomyocyte hypertrophy in vitro and in vivo","volume":"276","author":"Liang","year":"2001","journal-title":"J Biol Chem"},{"key":"2022102612014274600_ehab347-B30","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/cid\/ciy874","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenzaa","volume":"68","author":"Uyeki","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2022102612014274600_ehab347-B31","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1161\/CIRCULATIONAHA.117.031139","article-title":"Functional metabolomics characterizes a key role for N-acetylneuraminic acid in coronary artery diseases","volume":"137","author":"Zhang","year":"2018","journal-title":"Circulation"},{"key":"2022102612014274600_ehab347-B32","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/j.biocel.2008.02.020","article-title":"Molecular regulation of cardiac hypertrophy","volume":"40","author":"Barry","year":"2008","journal-title":"Int J Biochem Cell Biol"},{"key":"2022102612014274600_ehab347-B33","first-page":"2046","article-title":"GATA-dependent recruitment of MEF2 proteins to target promoters","author":"Morin","year":"2000"},{"key":"2022102612014274600_ehab347-B34","doi-asserted-by":"crossref","first-page":"25775","DOI":"10.1074\/jbc.M203122200","article-title":"Combinatorial expression of GATA4, Nkx2-5, and serum response factor directs early cardiac gene activity","volume":"277","author":"Sepulveda","year":"2002","journal-title":"J Biol Chem"},{"key":"2022102612014274600_ehab347-B35","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0014-5793(03)00359-4","article-title":"Isoproterenol produces a rapid increase in sialidase activity in rat heart tissue and cardiomyocyte-derived H9c2 cells in culture","volume":"542","author":"Saito","year":"2003","journal-title":"FEBS Lett"},{"key":"2022102612014274600_ehab347-B36","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0022-2828(91)90104-T","article-title":"Effects of neuraminidase on cellular calcium and contraction in cultured cardiac myocytes","volume":"23","author":"Yee","year":"1991","journal-title":"J Mol Cell Cardiol"},{"key":"2022102612014274600_ehab347-B37","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"2022102612014274600_ehab347-B38","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1684\/epd.2016.0845","article-title":"Sialidoses","volume":"18","author":"Franceschetti","year":"2016","journal-title":"Epileptic Disord"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/42\/36\/3770\/46643866\/ehab347.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/42\/36\/3770\/46643866\/ehab347.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T12:05:02Z","timestamp":1666785902000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/42\/36\/3770\/6310286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,28]]},"references-count":38,"journal-issue":{"issue":"36","published-online":{"date-parts":[[2021,6,28]]},"published-print":{"date-parts":[[2021,9,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehab347","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9,21]]},"published":{"date-parts":[[2021,6,28]]}}}